Effect of SB-408124, an orexin A OX1R receptor antagonist, on the compulsive behavior and the level of anxiety after the vital stress in rats
- Authors: Tissen I.Y.1, Yakushina N.D.1, Lebedev A.A.1, Pshenichnaya A.G.1, Bychkov E.R.1, Tsykunov S.G.1, Shabanov P.D.1
-
Affiliations:
- Institute of Experimental Medicine
- Issue: Vol 16, No 1 (2018)
- Pages: 34-42
- Section: Articles
- URL: https://journals.rcsi.science/RCF/article/view/8778
- DOI: https://doi.org/10.17816/RCF16134-42
- ID: 8778
Cite item
Full Text
Abstract
Abstract. The effect of the orexin A OX1R receptor antagonist SB-408124 of on the compulsive behavior and the anxiety in rats after the presentation of vital stress in a number of behavioral tests: marble test, elevated plus maze, in the open field and in the test “resident intruder”. In the buring marble test, the behavioral components of the obsession (obsessive and obtrusive thoughts) and compulsions (obtrusive behavior), aimed to reduce anxiety, were modeled. Mental trauma was caused by a stressful effect, the essence of which was the experience of the animals of the circumstances of the death of a partner from the actions of a predator. A group of rats were placed once in the terrarium to a tiger python. After the action of vital mental stress in rats, two connected behavioral phenomena were observed: a high level of anxiety and an increase in the number of buried balls. This was accompanied by a decrease in communicability. Intranasal administration (for 7 days) of orexin A antagonist OX1R receptor SB-408124 after presentation of the vital stress reduced the level of anxiety, and also normalized the communicative activity of animals and the number of buried balls, i.e. compulsive behavior. Thus, the orexin system of the brain is an important component of psychotraumatic mechanism. OX1R antagonists of orexin A receptors can potentially be considered as correctors of obsessive-compulsive disorders on the background of posttraumatic stress disorder (PTSD). Use of intranasal administration of OX1R antagonists of orexin A receptors in the clinic will allow the use of small doses of substances and thereby reduce their possible toxic effects.
Full Text
##article.viewOnOriginalSite##About the authors
Ilia Yu. Tissen
Institute of Experimental Medicine
Author for correspondence.
Email: aalebedev-iem@rambler.ru
PhD, Researcher, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgNatalia D. Yakushina
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
Post-graduate Student, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgAndrei A. Lebedev
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
Dr. Biol. Sci. (Pharmacology), Leading Researcher, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgAnna G. Pshenichnaya
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
Researcher, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgEugenii R. Bychkov
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
PhD (Biochemistry), Leading Researcher, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgSergei G. Tsykunov
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
Dr. Med. Sci. (Physiology), Professor, Head of Laboratory, I.P. Pavlov Dept. of Physiology
Russian Federation, Saint PeresburgPetr D. Shabanov
Institute of Experimental Medicine
Email: pdshabanov@mail.ru
Dr. Med. Sci., Professor, Head, S.V. Anichkov Department of Neuropharmacology
Russian Federation, Saint PeresburgReferences
- Лебедев А.А., Пшеничная А.Г., Бычков Е.Р., и др. Анта гонист рецепторов кортиколиберина астрессин снимает тревожно-фобические состояния у крыс, выращенных в социальной изоляции // Обзоры по клинической фармакологии и лекарственной терапии. – 2016. – Т. 14. – № 4. – С. 24–31. [Lebedev AA, Pshenichnaya AG, Bychkov ER, et al. Astressin, an antagonist of CRF receptors, reduces anxiety and fobial states in rats reared in social isolation conditions. Reviews on clinical pharmacology and drug therapy. 2016;14(4):24-31. (In Russ.)]
- Лебедев А.А., Шумилов Е.Г., Смирнов А.А., и др. Участие нейропептида орексина А в механизмах под крепления, активируемых психостимуляторами // Наркология. – 2015. – Т. 14. – № 2. – С. 12–18. [Le be dev AA, Shumilov EG, Smirnov AA, et al. Participation of the oryxine A neuropeptide in reinforcement me chanisms activated by psychostimulants. Narkologiia. 2015;14(2):12-18. (In Russ.)]
- Цикунов С.Г., Клюева Н.Н., Кусов А.Г., и др. Изменение липидного спектра сыворотки крови и печени крыс, вызванное тяжелой психогенной травмой // Бюллетень экспериментальной биологии и медицины. – 2006. – Т. 141. – № 5. – С. 575–578. [Tsikunov SG, Klyu eva NN, Kusov AG, et al. Changes in the lipid composition of blood plasma and liver in rats induced by severe psychic trauma. Biull Eksp Biol Med. 2006;141(5):575-578. (In Russ.)]
- Шабанов П.Д., Лебедев А.А. Угнетение самостимуляции латерального гипоталамуса опиатами и опиоидами, вводимыми в центральное ядро миндалины у крыс // Российский физиологический журнал им. И.М.Сеченова. – 2011. – Т. 97. – № 2. – С. 180–188. [Shabanov PD, Lebedev AA. The extended amygdala system and self-stimulation of the lateral hypothalamus in rats: modulation with opiates and opioids. Russian journal of physiology. 2011;97(2):180-188. (In Russ.)]
- Шабанов П.Д., Лебедев А.А. Участие ГАМК- и дофамин ергических механизмов ядра ложа конечной полоски в подкрепляющих эффектах психотропных средств, реализуемых через латеральный гипоталамус // Российский физиологический журнал им. И.М. Сеченова. – 2011. – Т. 97. – № 8. – С. 804–813. [Shabanov PD, Lebedev AA. Participation of gaba- and dopaminergic mechanisms of the bed nucleus of stria terminalis in reinforcing effects of psychotropic drugs mediated via the lateral hypothalamus. Russian journal of physiology. 2011;97(8):804-813. (In Russ.)]
- Шабанов П.Д., Лебедев А.А., Мещеров Ш.К. Дофамин и подкрепляющие системы мозга. – СПб.: Лань, 2002. [Shabanov PD, Lebedev AA, Meshcherov SK. Dopamine and reinforcing brain systems. Saint Petersburg: Lan’; 2002. (In Russ.)]
- Шабанов П.Д., Лебедев А.А., Якушина Н.Д., и др. Моделирование обсессивно-компульсивного и аддик тивного игрового поведения у крыс введением фенамина в тесте закапывания шариков // Наркология. – 2017. – Т. 16. – № 1. – С. 32–38. [Shabanov PD, Lebedev AA, Yakushina ND, et al. Modeling the obsessive-compulsive and addictive gambling behavior in a rat marble test by means of amphetamine administration. Narkologiia. 2017;16(1):32-38. (In Russ.)]
- Шабанов П.Д., Русановский В.В., Лебедев А.А. Зоосоциальное поведение млекопитающих. – СПб.: Медкнига «ЭЛБИ», 2006. [Shabanov PD, Rusanovskiy VV, Lebedev AA. Zoosocial behavior of mammalians. Saint Petersburg: Medkniga “ELBI”; 2006. (In Russ.)]
- Albelda N, Joel D. Current animal models of obsessive compulsive disorder: an update. Neuroscience. 2012;211:83-106. doi: 10.1016/j.neuroscience.2011.08.070.
- Blampied NM, Kirk RC. Defensive burying: Effects of diazepam and oxprenolol measured in extinction. Life Sci. 1983;33(8):695-699. doi: 10.1016/0024-3205(83)90773-7.
- Boutrel B, de Lecea L. Addiction and arousal: the hypocretin connection. Physiol Behav. 2008;93(4-5):947-951. doi: 10.1016/j.physbeh.2007.11.022.
- Craft RM, Howard JL, Pollard GT. Conditioned defensive burying as a model for identifying anxiolytics. Pharmacol Biochem Behav. 1988;30(3):775-780. doi: 10.1016/0091-3057(88)90098-6.
- de Lecea L. Hypocretins and the neurobiology of sleep-wake mechanisms. Prog Brain Res. 2012;198:15-24. doi: 10.1016/B978-0-444-59489-1.00003-3.
- Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233-242. doi: 10.2147/NDT.S3149.
- Flores A, Saravia R, Maldonado R, Berrendero F. Orexins and fear: implications for the treatment of anxiety disorders. Trends Neurosci. 2015;38(9):550-559. doi: 10.1016/j.tins.2015.06.005.
- Ida T, Nakahara K, Murakami T, et al. Possible involvement of orexin in the stress reaction in rats. Biochem Biophys Res Commun. 2000;270(1):318-323. doi: 10.1006/bbrc.2000.2412.
- Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):374-388. doi: 10.1016/j.pnpbp.2005.11.006.
- Kalinina T, Kudryashov N, Naplekova P, et al. P.1.h.032 Interaction of antidepressants with mild chronic stress: behavioural effects and content of monoamines and their metabolites in mouse brain. Eur Neuropsychopharmacol. 2014;24:S288. doi: 10.1016/s0924-977x(14)70455-9.
- Kayaba Y, Nakamura A, Kasuya Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003;285(3):R581-593. doi: 10.1152/ajpregu.00671.2002.
- Koob GF. Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry. 2009;42 Suppl 1:S32-41. doi: 10.1055/s-0029-1216356.
- Leeman RF, Potenza MN. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl). 2012;219(2):469-490. doi: 10.1007/s00213-011-2550-7.
- Li Y, Wang H, Qi K, et al. Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal. Physiol Behav. 2011;102(1):42-50. doi: 10.1016/j.physbeh.2010.10.006.
- Marazziti D, Carlini M, Dell’Osso L. Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia. Curr Top Med Chem. 2012;12(4):238-253. doi: 10.2174/1568026799078688.
- Naumenko VS, Bazovkina DV, Semenova AA, et al. Effect of glial cell line-derived neurotrophic factor on behavior and key members of the brain serotonin system in mouse strains genetically predisposed to behavioral disorders. J Neurosci Res. 2013;91(12):1628-1638. doi: 10.1002/jnr.23286.
- Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996-10015.
- Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-585. doi: 10.1016/S0092-8674(00)80949-6.
- Stricker-Krongrad A, Beck B. Modulation of hypothalamic hypocretin/orexin mRNA expression by glucocorticoids. Biochem Biophys Res Commun. 2002;296(1):129-133. doi: 10.1016/s0006-291x(02)00848-3.
- Tissen I, Vinogradov PM, Khokhlov PP, et al. P1.g.061 Orexin receptor type 1 (Ox1R) are involved in the formation and reinstatement of conditioned place preference. Eur Neuropsychopharmacol. 2015;25:S269-S270. doi: 10.1016/s0924-977x(15)30313-8.
- Veale D, Roberts A. Obsessive-compulsive disorder. BMJ. 2014;348:g2183. doi: 10.1136/bmj.g2183.
- Winsky-Sommerer R, Yamanaka A, Diano S, et al. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci. 2004;24(50):11439-11448. doi: 10.1523/JNEUROSCI.3459-04.2004.
